NASDAQ:PRTK - Paratek Pharmaceuticals Stock Price, Forecast & News

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) released its earnings results on Tuesday, November, 12th. The specialty pharmaceutical company reported ($1.00) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.06) by $0.06. The specialty pharmaceutical company earned $3.93 million during the quarter, compared to analysts' expectations of $3.63 million. Paratek Pharmaceuticals had a negative net margin of 505.07% and a negative return on equity of 5,327.73%. View Paratek Pharmaceuticals' Earnings History.

Paratek Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Paratek Pharmaceuticals.

Paratek Pharmaceuticals will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

7 Wall Street analysts have issued 1 year price targets for Paratek Pharmaceuticals' shares. Their forecasts range from $6.00 to $36.00. On average, they anticipate Paratek Pharmaceuticals' stock price to reach $17.33 in the next year. This suggests a possible upside of 382.8% from the stock's current price. View Analyst Price Targets for Paratek Pharmaceuticals.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Paratek Pharmaceuticals.

Press coverage about PRTK stock has been trending negative this week, InfoTrie reports. The research group scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Paratek Pharmaceuticals earned a media sentiment score of -2.2 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Paratek Pharmaceuticals.

Paratek Pharmaceuticals saw a decline in short interest in January. As of January 31st, there was short interest totalling 7,770,000 shares, a decline of 5.9% from the January 15th total of 8,260,000 shares. Based on an average daily volume of 1,224,700 shares, the short-interest ratio is currently 6.3 days. Currently, 28.1% of the shares of the stock are short sold. View Paratek Pharmaceuticals' Current Options Chain.

Some companies that are related to Paratek Pharmaceuticals include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Aduro BioTech (ADRO), Exelixis (EXEL), Verastem (VSTM), EXACT Sciences (EXAS), Energy Transfer LP Unit (ET), Progenics Pharmaceuticals (PGNX), TG Therapeutics (TGTX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO) and Omeros (OMER).

Paratek Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (2.04%), General American Investors Co. Inc. (1.94%), ICM Asset Management Inc. WA (1.35%), Water Island Capital LLC (1.26%), Goldman Sachs Group Inc. (1.03%) and Roumell Asset Management LLC (1.02%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Jeffrey Stein, Michael Bigham, Randall B Brenner, Thomas John Dietz and William M Haskel. View Institutional Ownership Trends for Paratek Pharmaceuticals.

PRTK stock was sold by a variety of institutional investors in the last quarter, including Roumell Asset Management LLC, General American Investors Co. Inc., J. Goldman & Co LP, Trellus Management Company LLC, Water Island Capital LLC and Raymond James & Associates. Company insiders that have sold Paratek Pharmaceuticals company stock in the last year include Adam Woodrow, Evan Loh, Randall B Brenner and William M Haskel. View Insider Buying and Selling for Paratek Pharmaceuticals.

PRTK stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., ICM Asset Management Inc. WA, Smith Asset Management Group LP, Banco Bilbao Vizcaya Argentaria S.A., Stifel Financial Corp, Oxford Asset Management LLP, Marshall Wace LLP and New York State Common Retirement Fund. View Insider Buying and Selling for Paratek Pharmaceuticals.

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PRTK stock can currently be purchased for approximately $3.59.

Paratek Pharmaceuticals has a market capitalization of $119.51 million and generates $17.12 million in revenue each year. The specialty pharmaceutical company earns $-112,360,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis. Paratek Pharmaceuticals employs 101 workers across the globe.View Additional Information About Paratek Pharmaceuticals.

The official website for Paratek Pharmaceuticals is http://www.paratekpharma.com/.

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]